SCHEMBL20705618

SCHEMBL20705618

O=C(O)C(Cc1ccccc1)N1C(=O)S/C(=C/c2ccco2)C1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.63
▸ ALDH1A1 P00352 6/20 0.63
▸ MEN1 O00255 5/20 0.63
▸ KMT2A Q03164 5/20 0.63
▸ POLB P06746 4/20 0.63
▸ RECQL P46063 2/20 0.63
▸ TDP1 Q9NUW8 2/20 0.63
▸ L3MBTL1 Q9Y468 2/20 0.63
▸ KDM4E B2RXH2 1/20 0.63
▸ PSMD14 O00487 1/20 0.63
▸ USP2 O75604 1/20 0.63
▸ MMP2 P08253 1/20 0.63
▸ THRB P10828 1/20 0.63
▸ BLM P54132 1/20 0.63
▸ MCL1 Q07820 4/20 0.62
▸ MME P08473 2/20 0.54
▸ BCL2L1 Q07817 1/20 0.54
▸ LMNA P02545 1/20 0.52
▸ ALOX12 P18054 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14680251 0.89 MAPT (0.78) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL19425474 0.79 MAPT (0.52) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL14680220 0.77 MAPT (1.00) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL26458902 0.77 MAPT (1.00) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL13748183 0.77 MCL1 (1.00) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL15502362 0.77 MAPT (0.56) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL8181654 0.72 KDR (0.69) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL8181657 0.72 KDR (0.69) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL19430434 0.72 MAPT (1.00) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL13186618 0.71 MEN1 (0.62) MAPTALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease UNITY BIOTECHNOLOGY, INC. (US) 2019-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease TP53, CDKN1A, GLA MAPT 1460/4885ALDH1A1 194/4885MEN1 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback